BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Handy CE, Antonarakis ES. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol. 2018;14:907-917. [PMID: 29260582 DOI: 10.2217/fon-2017-0531] [Cited by in Crossref: 52] [Cited by in F6Publishing: 37] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Vlaeminck-Guillem V. Exosomes and prostate cancer management. Semin Cancer Biol 2021:S1044-579X(21)00216-9. [PMID: 34384877 DOI: 10.1016/j.semcancer.2021.08.004] [Reference Citation Analysis]
2 Akkın S, Varan G, Bilensoy E. A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers. Molecules 2021;26:3382. [PMID: 34205019 DOI: 10.3390/molecules26113382] [Reference Citation Analysis]
3 Altschuler J, Stockert JA, Kyprianou N. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance. Int J Mol Sci 2021;22:2100. [PMID: 33672595 DOI: 10.3390/ijms22042100] [Reference Citation Analysis]
4 Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther 2021;6:72. [PMID: 33608497 DOI: 10.1038/s41392-020-00449-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Bagley SJ, Desai AS, Nasrallah MP, O'Rourke DM. Immunotherapy and Response Assessment in Malignant Glioma: Neuro-oncology Perspective. Top Magn Reson Imaging 2020;29:95-102. [PMID: 32271286 DOI: 10.1097/RMR.0000000000000233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Malinowski B, Wiciński M, Musiała N, Osowska I, Szostak M. Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer-A Comprehensive Review. Diagnostics (Basel) 2019;9:E161. [PMID: 31731466 DOI: 10.3390/diagnostics9040161] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
7 Rathi N, McFarland TR, Nussenzveig R, Agarwal N, Swami U. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. Drugs 2021;81:191-206. [PMID: 33369720 DOI: 10.1007/s40265-020-01456-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chuang YC, Tseng JC, Huang LR, Huang CM, Huang CF, Chuang TH. Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade. Front Immunol 2020;11:1075. [PMID: 32547560 DOI: 10.3389/fimmu.2020.01075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
9 Shindo Y, Hazama S, Tsunedomi R, Suzuki N, Nagano H. Novel Biomarkers for Personalized Cancer Immunotherapy. Cancers (Basel) 2019;11:E1223. [PMID: 31443339 DOI: 10.3390/cancers11091223] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
10 Guth A, Monk E, Agarwal R, Bergman BC, Zemski-Berry KA, Minic A, Jordan K, Schlaepfer IR. Targeting Fat Oxidation in Mouse Prostate Cancer Decreases Tumor Growth and Stimulates Anti-Cancer Immunity. Int J Mol Sci 2020;21:E9660. [PMID: 33352903 DOI: 10.3390/ijms21249660] [Reference Citation Analysis]
11 Ruan S, Greenberg Z, Pan X, Zhuang P, Erwin N, He M. Extracellular Vesicles as an Advanced Delivery Biomaterial for Precision Cancer Immunotherapy. Adv Healthc Mater 2021;:e2100650. [PMID: 34197051 DOI: 10.1002/adhm.202100650] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cook K, Durrant L, Brentville V. Current Strategies to Enhance Anti-Tumour Immunity. Biomedicines 2018;6:37. [DOI: 10.3390/biomedicines6020037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Salgia R, Jolly MK, Dorff T, Lau C, Weninger K, Orban J, Kulkarni P. Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. J Clin Med 2018;7:E156. [PMID: 29914187 DOI: 10.3390/jcm7060156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
14 Khalvandi A, Abolhasani M, Madjd Z, Shekarabi M, Kourosh-Arami M, Mohsenzadegan M. Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer. APMIS 2021;129:291-303. [PMID: 33743542 DOI: 10.1111/apm.13132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhao H, Ma J, Lei T, Ma W, Zhang M. The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer. Invest New Drugs 2019;37:810-7. [PMID: 30374653 DOI: 10.1007/s10637-018-0683-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology 2018;7:e1433982. [PMID: 29872569 DOI: 10.1080/2162402X.2018.1433982] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 8.3] [Reference Citation Analysis]
17 Luan J, Zhang Q, Song L, Wang Y, Ji C, Cong R, Zheng Q, Xu Z, Xia J, Song N. Identification and validation of a six immune-related gene signature for prediction of biochemical recurrence in localized prostate cancer following radical prostatectomy. Transl Androl Urol 2021;10:1018-29. [PMID: 33850736 DOI: 10.21037/tau-20-1231] [Reference Citation Analysis]
18 Yekedüz E, Utkan G, Kanesvaran R, Ürün Y. Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same? Prostate Int 2021;9:1-5. [PMID: 33912507 DOI: 10.1016/j.prnil.2020.03.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Panunzio A, Tafuri A, Princiotta A, Gentile I, Mazzucato G, Trabacchin N, Antonelli A, Cerruto MA. Omics in urology: An overview on concepts, current status and future perspectives. Urologia 2021;:3915603211022960. [PMID: 34169788 DOI: 10.1177/03915603211022960] [Reference Citation Analysis]
20 Mehanny M, Lehr CM, Fuhrmann G. Extracellular vesicles as antigen carriers for novel vaccination avenues. Adv Drug Deliv Rev 2021;173:164-80. [PMID: 33775707 DOI: 10.1016/j.addr.2021.03.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Zhang X, Liu C, Li K, Wang K, Zhang Q, Cui Y. Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer. Medicine (Baltimore) 2019;98:e14254. [PMID: 30732140 DOI: 10.1097/MD.0000000000014254] [Reference Citation Analysis]
22 Reuven EM, Leviatan Ben-Arye S, Yu H, Duchi R, Perota A, Conchon S, Bachar Abramovitch S, Soulillou JP, Galli C, Chen X, Padler-Karavani V. Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy. ACS Nano 2019;13:2936-47. [PMID: 30840433 DOI: 10.1021/acsnano.8b07241] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
23 Zhang C, Shen L, Qi F, Wang J, Luo J. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma. J Cell Physiol 2020;235:3849-63. [PMID: 31596511 DOI: 10.1002/jcp.29279] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
24 Moussa M, Papatsoris A, Abou Chakra M, Sryropoulou D, Dellis A. Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Expert Opin Pharmacother 2020;21:1431-48. [PMID: 32469248 DOI: 10.1080/14656566.2020.1767069] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
25 Gamat-Huber M, Jeon D, Johnson LE, Moseman JE, Muralidhar A, Potluri HK, Rastogi I, Wargowski E, Zahm CD, McNeel DG. Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). Cancers (Basel) 2020;12:E2831. [PMID: 33008010 DOI: 10.3390/cancers12102831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Sasso E, D'Alise AM, Zambrano N, Scarselli E, Folgori A, Nicosia A. New viral vectors for infectious diseases and cancer. Semin Immunol 2020;50:101430. [PMID: 33262065 DOI: 10.1016/j.smim.2020.101430] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
27 Bou-Dargham MJ, Sha L, Sang QA, Zhang J. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy. BMC Cancer 2020;20:572. [PMID: 32552802 DOI: 10.1186/s12885-020-07058-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
28 Linder S, van der Poel HG, Bergman AM, Zwart W, Prekovic S. Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. Endocr Relat Cancer 2018;26:R31-52. [PMID: 30382692 DOI: 10.1530/ERC-18-0289] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
29 Guan Y, Xiong H, Feng Y, Liao G, Tong T, Pang J. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer Prostatic Dis 2020;23:220-31. [PMID: 32034294 DOI: 10.1038/s41391-020-0209-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
30 Baxevanis CN, Fortis SP, Perez SA. Prostate cancer: any room left for immunotherapies? Immunotherapy 2019;11:69-74. [DOI: 10.2217/imt-2018-0159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
31 Wu Z, Man S, Sun R, Li Z, Wu Y, Zuo D. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer. International Immunopharmacology 2020;85:106613. [DOI: 10.1016/j.intimp.2020.106613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
32 Parayath N, Padmakumar S, Nair SV, Menon D, Amiji MM. Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. Regen Eng Transl Med 2020;6:29-49. [DOI: 10.1007/s40883-019-00113-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Kvízová J, Pavlíčková V, Kmoníčková E, Ruml T, Rimpelová S. Quo Vadis Advanced Prostate Cancer Therapy? Novel Treatment Perspectives and Possible Future Directions. Molecules 2021;26:2228. [PMID: 33921501 DOI: 10.3390/molecules26082228] [Reference Citation Analysis]
34 Savoy M. What's New in Vaccine Science. Prim Care 2020;47:517-28. [PMID: 32718447 DOI: 10.1016/j.pop.2020.05.006] [Reference Citation Analysis]
35 Varadé J, Magadán S, González-Fernández Á. Human immunology and immunotherapy: main achievements and challenges. Cell Mol Immunol 2021;18:805-28. [PMID: 32879472 DOI: 10.1038/s41423-020-00530-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
36 Bou-Dargham MJ, Sang QA. Secretome analysis reveals upregulated granzyme B in human androgen-repressed prostate cancer cells with mesenchymal and invasive phenotype. PLoS One 2020;15:e0237222. [PMID: 32764784 DOI: 10.1371/journal.pone.0237222] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]